Non‐invasive molecular biomarkers for monitoring solid organ transplantation: A comprehensive overview

Abstract

Solid organ transplantation is a life‐saving intervention for individuals with end‐stage organ failure. Despite the effectiveness of immunosuppressive therapy, the risk of graft rejection persists in all viable transplants between individuals. The risk of rejection may vary depending on the degree of compatibility between the donor and recipient for both human leucocyte antigen (HLA) and non‐HLA gene‐encoded products. Monitoring the status of the allograft is a critical aspect of post‐transplant management, with invasive biopsies being the standard of care for detecting rejection. Non‐invasive biomarkers are increasingly being recognized as valuable tools for aiding in the detection of graft rejection, monitoring graft status and evaluating the efficacy of immunosuppressive therapy. Here, we focus on the importance of molecular biomarkers in solid organ transplantation and their potential role in clinical practice. Conventional molecular biomarkers used in transplantation include HLA typing, detection of anti‐HLA antibodies, killer cell immunoglobulin–like receptor genotypes, and anti‐MHC class 1–related chain A antibodies, which are important for assessing the compatibility of the donor and recipient. Emerging molecular biomarkers include the detection of donor‐derived cell‐free DNA, microRNAs (regulation of gene expression), exosomes (small vesicles secreted by cells), and kidney solid organ response test, in the recipient's blood for early signs of rejection. This review highlights the strengths and limitations of these molecular biomarkers and their potential role in improving transplant outcomes.